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Abstract23
Cancer cells depend on glucose metabolism via glycolysis as a primary energy source, despite 24 
the presence of oxygen and fully functioning mitochondria, in order to promote growth, 25 
proliferation and longevity. Glycolysis relies upon NAD+ to accept electrons in the 26 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reaction, linking the redox state of the 27 
cytosolic NAD+ pool to glycolytic rate. The free cytosolic NAD+/NADH ratio is involved in 28 
over 700 oxidoreductive enzymatic reactions and as such, the NAD+/NADH ratio is regarded 29 
as a metabolic readout of overall cellular redox state. Many experimental techniques that 30 
monitor or measure total NAD+ and NADH are unable to distinguish between protein-bound 31 
and unbound forms. Yet total NAD+/NADH measurements yield little information, since it is 32 
the free forms of NAD+ and NADH that determine the kinetic and thermodynamic influence 33 
of redox potential on glycolytic rate. Indirect estimations of free NAD+/NADH are based on 34 
the lactate/pyruvate (L/P) ratio at chemical equilibrium, but these measurements are often 35 
undermined by high lability. To elucidate the sensitivity of the free NAD+/NADH ratio to 36 
changes in extracellular substrate, an in silico model of hepatocarcinoma glycolysis was 37 
constructed and validated against in vitro data. Model simulations reveal that over 38 
experimentally relevant concentrations, changes in extracellular glucose and lactate 39 
concentration during routine cancer cell culture can lead to significant deviations in the 40 
NAD+/NADH ratio. Based on the principles of chemical equilibrium, the model provides a 41 
platform from which experimentally challenging situations may be examined, suggesting that 42 
extracellular substrates play an important role in cellular redox and bioenergetic homeostasis.  43 
Introduction 44 
Cellular bioenergetics describe the processes that generate energy in the form of ATP within 45 
the cell, achieved primarily via aerobic and anaerobic glycolysis, pyruvate and fatty acid 46 
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oxidation, and oxidative phosphorylation within the mitochondria [1,2]. When glycolysis is 47
coupled to oxidative phosphorylation, the NADH reducing equivalents produced in the cytosol 48 
by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shuttled to the mitochondrial 49 
matrix where they are consumed by the respiratory chain. In the absence of oxygen, when 50 
mitochondria are unable to recycle the NADH to NAD+, lactate dehydrogenase provides an 51 
alternate means of oxidizing NADH to NAD+ to facilitate anaerobic glycolysis [3]. Tumours 52 
and highly-proliferating cells can show increased uptake of glucose, favouring glycolytic 53 
production of lactate, despite the presence of oxygen and fully functioning mitochondria [4]. 54 
The process of aerobic glycolysis under these conditions is also known as the Crabtree Effect, 55 
which is inefficient at producing ATP compared to the complete oxidation of glucose coupled 56 
to oxidative phosphorylation in terms of stoichiometric conversion of glucose to ATP [5]. 57 
However, the glycolytic rate can be considerably higher than oxidative respiration, and it has 58 
been suggested that this results in total ATP synthesis that is comparable over any given time, 59 
for either route of glucose metabolism [6]. Aerobic glycolysis in tumours and proliferating cells 60 
is recognised as an adaptive mechanism to facilitate rapid ATP production, aid survival and 61 
allow cells to thrive in the tumour microenvironment, and also to meet the elevated levels of 62 
biosynthesis required to support uncontrolled proliferation [7]. In turn, proliferating cells have 63 
a higher demand for reducing equivalents, in the form of NADH, which contributes to the 64 
NAD+/NADH ratio [8]. Therefore, an inextricable link exists between aerobic glycolytic rate 65 
and free NAD+/NADH redox state. 66 
Current in vitro techniques for investigating the NAD+ pool redox state are only capable of 67 
measuring total NAD+ and NADH without discriminating between free and protein-bound 68 
forms [9]. This is problematic, as only free NAD+/NADH regulate cellular redox state, limiting 69 
the insight that can be gleaned from the total NAD+/NADH measurement. Free NAD+/NADH 70 
may be estimated or derived via: (i) exploitation of the lactate/pyruvate (L/P) ratio at 71 
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equilibrium [10]; (ii) using hyperpolarised glucose [11]; or (iii) using genetically encoded 72
sensors (SoNAR) [12]. Estimation of the free NAD+/NADH ratio using the L/P ratio is the 73 
most widely used approach, founded on the principles of chemical equilibrium, i.e., when the 74 
conversion between pyruvate + NADH and lactate + NAD+ is at equilibrium, the free 75 
NAD+/NADH ratio can be calculated by the following equation: 76 
 77 
where,  78 
 79 
To use this method, the accurate definition of the equilibrium status for the conversion of the 80 
L/P ratio is crucial to correctly estimate the NAD+/NADH ratio [9]. Specifically, studies which 81 
assume the conversion is at equilibrium, whilst failing to confirm how close it is, can result in 82 
estimated ratios that are 1 to 2 orders of magnitude away from the true value. This is because 83 
the mass action reaction quotient (Q) at near equilibrium can differ between 1 and 2 orders of 84 
magnitude [13 19]. When Q = Keq, the forward and reverse rates of conversion are equal and 85 
there is no net loss or gain of lactate. However, when Q < Keq, the reaction favours formation 86 
of lactate and similarly, when Q > Keq, the reaction favours formation of pyruvate [9]. In 87 
cultured cancer cells, the conversion is predominantly from pyruvate to lactate, due to the rapid 88 
disposal of lactate via monocarboxylate transporters (MCTs) located on the plasma membrane 89 
[20,21]. This is a function of the high glycolytic rates found in cancer cells, which results in 90 
excessive production of pyruvate and NADH that is beyond the metabolic capacity of 91 
mitochondrial shuttles and pyruvate dehydrogenase [22]. To utilise the L/P ratio conversion to 92 
estimate free NAD+/NADH, one must force chemical equilibrium in vitro by elevating 93 
extracellular lactate concentrations between 16 and 22 mM [9]. However, in doing so, glucose 94 
consumption is seen to significantly reduce [9], thus demonstrating that the manipulation of 95 
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extracellular lactate concentrations artificially alters the state of cellular lactate equilibrium 96
while simultaneously perturbing glucose and energy metabolism. 97 
One way of determining glycolytic rate in vitro is by extracellular flux analysis (EFA), which 98 
is relatively high throughput and experimentally inexpensive [23 25]. This method quantifies 99 
cellular respiration in the form of oxygen consumption rate (OCR) and extracellular 100 
acidification rate (ECAR). ECAR can be used as a measure of glycolytic rate when it is 101 
assumed that lactic acid, the terminal product of glycolysis, dissociates in the extracellular 102 
environment to a proton (H+) and lactate anion at physiological pH. Recently, the significance 103 
of respiratory contributions to ECAR has been highlighted, illustrating that the release of CO2 104 
via oxidative phosphorylation can lead to the formation and dissociation of carbonic acid 105 
(H2CO3), amplifying and potentially distorting the ECAR output when used to assess glycolytic 106 
rate [26]. Fortunately, the proportion of respiratory acidification and glycolytic-only 107 
acidification can be easily calculated using the extracellular media buffering power (BP) [27]. 108 
This differentiation of acidification sources is necessary, as different cell types under different 109 
culture conditions may acidify the extracellular environment almost entirely via glycolysis or 110 
respiration [27]. Therefore, glycolytic proton production rate (PPRgly) is considered a more 111 
accurate representation of glycolytic rate compared to ECAR [27]. Current in silico models 112 
that focus specifically on hepatocellular bioenergetics in combination with EFA, are lacking in 113 
metabolic network depth and, as a result, authors tend to mathematically express glycolytic 114 
rate as pyruvate-to-lactate flux, rather than proton release into an extracellular environment, 115 
omitting respiratory contributions to ECAR altogether [27].  116 
This study describes the construction, parameterisation and validation of an in silico model of 117 
hepatocarcinoma cell glycolysis used to investigate: (i) the sensitivity of the NAD+/NADH 118 
redox ratio to perturbations in extracellular lactate and glucose concentrations; and (ii) changes 119 
to GAPDH and LDH enzyme fluxes during variations in the extracellular substrate. The model 120 
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described, captures the rapid binding and unbinding between protons and metal ions with all 121
modelled biochemical species. This allows for the computation of the dynamic changes in pH 122 
from the total proton stoichiometry, which is crucial when simulating in vitro PPRgly as a 123 
function of H+/lactate efflux into an extracellular environment. The model is validated against 124 
in vitro hepatocarcinoma EFA and NAD+-ATP data, to confirm the ability of the model to 125 
recreate the relationship between the two outputs. The HepG2 cell line was used due to the 126 
substantial number of studies that utilise these cells as a hepatic in vitro model for the study of 127 
bioenergetic toxicity [26,27]. Furthermore, this immortalized cell line was favoured over 128 
primary cells, as cancer cells are renowned for utilising the glycolytic pathway for the 129 
generation of cellular energy (ATP) over oxidative phosphorylation as a result of the Warburg 130 
effect, facilitating the study of ECAR as a function of glycolytic flux [5,27]. The two-point 131 
validation allows for changes in glycolytic rate as a function of NAD+/NADH perturbations to 132 
be explored. This approach aims to provide a platform from which aerobic glycolytic flux as a 133 
function of experimentally challenging situations may be investigated. 134 
Materials and methods 135 
In silico.  136 
Model development. 137 
The mathematical model of hepatic glycolysis consists of 26 state variables, 14 enzyme-138 
mediated reactions and two transport fluxes, occurring in two compartments: cytoplasm and 139 
extracellular space (Fig 1). Variable and reaction abbreviations are given in Tables 1 and 2 140 
respectively. Reaction and transporter kinetics are modelled using kinetic terms and parameters 141 
sourced from the literature, or by fitting to experimental flux data. A comprehensive list of all 142 
kinetic terms can be found in the S1 Supporting Information. Flux units for the model are given 143 
as mM min-1.  144 
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 145 
Fig 1. Schematic of the human hepatic bioenergetic model. The biochemical model comprises two 146 
compartments: cytoplasm and extracellular space. Glycolytic enzymes are shown in purple, transporter 147 
reactions are depicted as blue rectangles and additional reactions are portrayed in orange. Reaction 148 
descriptions can be found in Table 2. See S1 Supporting Information for additional information. 149 
 150 
Table 1:  Model biochemical reactants including their corresponding abbreviations (Fig 1), 151 
allocated compartment and initial concentration. 152 
Variable Abbreviation Compartment Initial Concentration (mM) 
Glucose GLC Cytoplasm 5.000 
ATP ATP Cytoplasm 2.800 
ADP ADP Cytoplasm 0.800 
Glucose-6-phosphate G6P Cytoplasm 0.120 
Fructose-6-phosphate F6P Cytoplasm 0.005 
Inorganic phosphate Pi Cytoplasm 5.000 
Fructose-1,6-phosphate F16P Cytoplasm 0.020 
1,3-bisphospho-glycerate BPG Cytoplasm 0.300 
Fructose-2,6-phosphate F26P Cytoplasm 0.004 
Dihydroxyacetone-
phosphate DHAP Cytoplasm 0.300 
Glyceraldehyde-
phosphate GHAP Cytoplasm 0.100 
NAD NAD Cytoplasm 1.220 
NADH NADH Cytoplasm 0.00056 
2-phospho-D-glycerate PG2 Cytoplasm 0.030 
3-phospho-D-glycerate PG3 Cytoplasm 0.270 
Phosphoenolpyruvate PEP Cytoplasm 0.150 
Pyruvate PYR Cytoplasm 0.100 
Lactate LAC Cytoplasm 0.500 
Protons H Cytoplasm 6.8 (pH) 
Magnesium ions Mg Cytoplasm 5.000 
Potassium ions K Cytoplasm 8.000 
Glucose GLCe Extracellular 5.000 
Lactate LACe Extracellular 0.000 
Protons He Extracellular 7.4 (pH) 
Magnesium ions  Mge Extracellular 0.000 
Potassium ions Ke Extracellular 0.000 
 
Extracellular  153 
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Table 2: Model enzyme-mediated reactions including abbreviations and descriptions (Fig 1).154
Reaction Abbreviation Description 
Glucokinase GLK GLC + ATP  ADP + G6P + H 
Glucose-6-phosphatase G6Pase G6P + H2O G6P+ Pi 
Phosphoglucose isomerase PGI G6P  F6P 
Phosphofructokinase PFK F6P + ATP  F16P + ADP + H 
Fructose-1,6-bisphosphatase FBP1 F16P + H2O  F6P + Pi 
Aldolase ALD F6P  DHAP + GAPH 
Triosephosphate isomerase TPI DHAP  GAPH 
Glyceraldehyde-3-Phosphate 
dehydrogenase GAPDH GAPH + Pi + NAD+  BPG + NADH + H 
Phosphoglycerate kinase PGK BPG + 2 ADP  PG3 + 2 ATP 
Phosphoglycerate mutase 1 PGM PG3  PG2 
Enolase / phosphopyruvate hydratase  ENO PG2  PEP 
Pyruvate Kinase PYK PEP + 2 ADP + H  PYR + 2 ATP 
Lactate dehydrogenase LDH PYR + NADH + H  LAC + NAD 
Glucose Storage (Glycogenolysis) FD GLC  Ø 
Glut-2-transporter GLUT2 GLCe  GLC 
Monocarboxylate transporter 1 MCT1 LAC+ H  LACe + He 
 
Single-headed reaction arrows indicate irreversible reactions and double arrows indicate reversible 155 
reactions. Full details of each reaction / transporter along with their corresponding parameter values can 156 
be found in the S1 Supporting Information. 157 
 158 
Modelling pH-dependent enzyme kinetics and reaction equilibria: BISEN. 159 
The hepatic glycolysis model was constructed in MATLAB®, utilising the Biochemical 160 
Simulation Environment (BISEN) suite [28]. BISEN is an open-source tool that assists in 161 
generating sets of differential equations for simulating biochemical systems, accounting for 162 
dynamic proton and metal ion buffering, thermodynamics and reaction equilibria. Detailed 163 
instructions on how to use BISEN have been previously published [28]. Briefly, the state 164 
variables refer to the biochemical reactants within the model which are the sum of its 165 
interconvertible biochemical species. For example, ATP is a reactant that represents the sum 166 
of its related species: ATP4-, HATP3-, MgATP2- etc. By accounting for the rapid 167 
interconversion of all species with metal ions and protons, the differences in state depending 168 
upon the pH can be modelled, whilst accounting for a complete proton stoichiometry. Each 169 
biochemical equation has its own associated equilibrium constant and the standard-state free 170 
energy of reaction, rG0, that is independent of pH yet dependent upon changes in temperature 171 
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and ionic strength. Overall, this allows favorability of a reaction to change as a result of a pH 172
change (29).   173 
Kinetic equations and parameters. 174 
Transporter and glycolysis enzyme reaction equations, as well as initial parameter estimates, 175 
are all sourced from the literature (Table 2), predominantly from a comprehensive model of 176 
human hepatic glucose metabolism from Koenig et al. [30].  Additional reaction equations and 177 
parameters are based on experimental data from the literature or described here in this paper. 178 
All literature sourced parameter values can be found in the S1 Supporting Information. For 179 
model alignment with experimental data, certain model parameters were adjusted using 180 
unconstrained nonlinear optimization (Nelder-Mead simplex algorithm), starting with an initial 181 
literature-based parameter estimate. All rate equations and parameters are liver specific and 182 
can be found in the S1 Supporting Information along with their corresponding references.  183 
Model simulations. 184 
Model simulations were produced via integration of the resulting ordinary differential 185 
equations (ODEs) (S1 Supporting Information) using the variable order stiff solver ode15s 186 
(MATLAB®). Compartment volumes were also set to mimic EFA by assigning the cytoplasm 187 
/ intracellular volume as the volume occupied by the 2.5 × 104 cells seeded per well, and the 188 
extracellular volume as 200 µl for the total extracellular volume of each well used in the EFA.  189 
In silico  in vitro PPRgly coupling. 190 
In silico PPRgly was simulated as a function of the MCT1 transport flux, , expressed in 191 
mM min-1. Conversion from in silico transport flux of mM min-1 to the in vitro PPRgly pmol 192 
min-1 / g protein measurement was accomplished using Equation 1. Note, this conversion 193 
equation also includes normalization for experimental protein content, where PNF is the 194 
protein normalization factor.  195 
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 (1)
In vitro. 196 
Materials. 197 
All extracellular flux analysis consumables were purchased from Seahorse Biosciences (North 198 
Billerica, MA, USA). HepG2 cells were purchased from the European Collection of Cell 199 
Phosphate Buffered Saline 200 
(PBS) and Rat tail Collagen I were purchased from Life Technologies (Paisley, UK). All other 201 
reagents were purchased from Sigma Aldrich (Dorset, UK).   202 
Cell culture. 203 
HepG2 cells were maintained in DMEM high-glucose media (glucose 25 mM) supplemented 204 
with foetal bovine serum (10% v/v), L-glutamine (2 mM), sodium pyruvate (1 mM) and 205 
HEPES (1 mM). Cells were incubated at 37oC under humidified air containing 5% CO2. Cells 206 
were used up to passage 17.  207 
Extracellular flux analysis assay. 208 
HepG2 cells were collected on the day of the experiment by trypsinisation and then washed 209 
thrice with serum- and glucose-free media. The cells were then plated onto a collagen coated 210 
(50 µg/ml in acetic acid 0.02 M) XFe 96-well cell culture microplates (2.5 × 104 cells/well) 211 
overnight in 100 µl of high glucose (25 mM) cell culture media. Before analysis, culture 212 
medium was removed from all wells and replaced with 175 µl of unbuffered glucose free 213 
Seahorse Assay media, supplemented with sodium pyruvate (1 %v/v) and L-glutamate (1% 214 
v/v), pre-warmed to 37oC. Cells were then incubated in a CO2 free incubator at 37oC for 1 h. 215 
Before rate measurement, the XFe96 Instrument (Seahorse biosciences, North Billerica, MA) 216 
mixed the assay media in each well for 10 min, allowing the oxygen partial pressure to 217 
equilibrate. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 218 
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were measured simultaneously thrice, establishing a baseline rate. For each measurement there 219
was a 3 min mix followed by 3 min wait time to restore normal oxygen tension and pH in the 220 
transient microenvironment surrounding the cells. Glucose injections (0.1  25 mM) of 25 µl 221 
occurred at the end of the basal measurement cycles at 16 min, followed by 10 further 222 
measurements. The overall assay duration was 95 min for each of the n = 4 experimental 223 
repeats. 224 
BCA protein quantification assay. 225 
Post extracellular flux analysis, assay medium was removed from all wells before the addition 226 
of 50 µl of Somatic cell ATP releasing agent (Sigma-Aldrich) to each well and the plate was 227 
carefully shaken (1 min, 300 RPM). A standard curve was prepared using a BCA stock (2 mg 228 
BCA/ml in ATP releasing agent). Working reagent (WR) was prepared by adding 50 parts 229 
bicinchoninic acid to 1 part copper sulphate. 5 µl of cell lysate was plated into a clear 96 well 230 
plate followed by addition of 200 µl of WR before incubation (37oC, for 30 min). The 231 
absorbance was then measured at 580 nm on a Labsystems Multiskan plate reader. Protein 232 
content was then extrapolated from the standard curve. Protein concentrations were then used 233 
to normalise the extracellular flux data, giving overall rates of ECAR and OCR as mpH min-1 234 
well protein-1 and pmol min-1 well protein-1, respectively. 235 
Buffering power. 236 
EFA assay media buffering capacity was measured at 37 oC using a pH probe. Hydrochloric 237 
acid (HCl) (0.1 M) was charged in 6 x 20 µl aliquots to 10 ml of assay media, while changes 238 
in pH were recorded. Media buffering power was calculated from the gradient of the line of 239 
best fit after plotting the change in pH vs nmol H+ added per 2 µl [31].  240 
PPRgly calculations. 241 
PPRgly was calculated from the ECAR measurements following the methodology of Mookerjee 242 
et. al (26,27). Briefly, ECAR was measured in units of mpH/min/well protein-1, representing 243 
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respiratory and glycolytic contributions to acidification. The total proton production rate, 244
PPRtot (pmol H+/min/ g protein), was calculated using Eq (2).  245 
  (2) 
The respiratory contributions to PPR, PPRresp (pmol H+/min/ g protein), were calculated using 246 
Equation 3, where  is the overall pKa for CO2(aq) + H2O  HCO3- = 6.093,  = 247 
1 is the derived acidification for the metabolic transformation of glucose oxidation, the average 248 
total amount of oxygen consumption, denoted , is equal to 17.78 pmol O2/min/ g 249 
protein for 5 mM over 10 measurements and non-respiratory oxygen consumption denoted 250 
, is equal to 5.17 pmol O2/min/ g protein. Thus, 251 
 (3) 
Finally, using Eq (4), PPRgly was calculated by subtracting respiratory acidification 252 
contributions from the total proton production rate: 253 
  (4) 
 254 
Statistical analysis.  255 
Statistical significance was ascertained using Prism 5 software via a one-way ANOVA, with 256 
values expressed as a mean ± standard deviation (S.D) taken from four independent 257 
experiments (n=4 experimental repeats). 258 
Results and discussion 259 
Extracellular flux analysis. 260 
The effects of changes in extracellular glucose concentration (0-25 mM) on PPRgly and OCR 261 
for HepG2 cells were examined (Fig 2).  262 
 263 
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Fig 2. The effect of extracellular glucose on PPRgly and OCR. HepG2 cells were exposed to 264
serial concentrations of glucose (0.1 to 25 mM) at t = 16 minutes. PPRgly and OCR values are 265 
normalised by the values obtained prior to glucose exposure and are expressed as the PPRgly 266 
and OCR ratios compared to zero glucose added.  Measurements are an average of n = 4 267 
experimental repeats. 268 
 269 
Prior to EFA, the cells were starved for 60 minutes in glucose-free media. Glucose was 270 
reintroduced after 16 minutes of EFA, stimulating increases in PPRgly ratio and decreases in 271 
OCR, for all concentrations of glucose (Fig.2). These results suggest that the introduction of 272 
extracellular glucose increases glycolytic energy metabolism, while diminishing respiratory 273 
energy production. An increase in glycolytic energy metabolism, facilitates ATP generation 274 
from glucose at a faster rate than oxidative phosphorylation. The ability of carcinoma cell lines, 275 
including HepG2, to exhibit this phenomena is well characterized and has been reported 276 
previously [4,32]. It is common practice to use high-glucose (25 mM) during routine cell 277 
culture. Fig 2 highlights how a high-glucose extracellular environment can influence cellular 278 
energy metabolism, illustrating that 25 mM glucose can yield up to a 7-fold increase in 279 
glycolytic-based energy metabolism when compared to a physiologically relevant extracellular 280 
glucose concentration (5 mM). In this instance, while glycolytic-based metabolism is primarily 281 
responsible for energy production, deducting respiratory contributions to extracellular 282 
acidification is an essential and facile endeavor for the sake of understanding the cellular 283 
bioenergetic output.  284 
Sensitivity analysis. 285 
Testing the sensitivity of a metabolic model with respect to its parameters is a crucial way of 286 
assessing its robustness. Variables that are most sensitive to parameter perturbation can be 287 
identified by measuring subsequent changes in time-course simulations and accordingly, any 288 
measurements or fluctuations in processes represented by these parameters must be carefully 289 
considered. Sensitivity analysis may be presented in many forms depending upon the state of 290 
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the system. For this model, the relative change of the jth variable with respect to a -99% to 291
+400% change in the ith parameter was measured (Eq 6).  is defined as the jth variable over 292 
time. More specifically,  is the jth variable with its base value;  is the jth variable 293 
with a perturbed value; with [-99,400%] of its base value, . Mean  is denoted 294 
as  the mean value of the jth variable over the time course  [0,300] min. Thus, our 295 
sensitivity metric, , is defined: 296 
 
  (6) 
A value of  would signify that the absolute, relative change in the mean of the variable 297 
over the time course is the same as the absolute, relative change in parameter. A parameter is 298 
classed as mildly sensitive (MS) if  is between 1 and 10. A parameter is sensitive (S) if  > 299 
10. The sensitivity analysis results for the model are given in Fig 3. This analysis identified 8 300 
key sensitive parameters: phosphofructokinase (PFK) Vmax (MS); triosephosphate isomerase 301 
(TPI) Keq (MS); dihydroxy-acetone phosphate (DHAP) Km (MS); glyceraldehyde 302 
dehydrogenase (GAPDH) Keq (MS); Km NAD+ (MS); lactate dehydrogenase (LDH) Vmax (MS); 303 
MCT1 Keq (S); and MCT1 Vmax (S). The two most sensitive parameters with respect to lactate, 304 
Keq and Vmax for the MCT1 transporter, are plotted as a % mean change of its initial value in 305 
Fig 4. With two out of three MCT1 transporter parameters registering as sensitive, parameter 306 
selection for this enzyme-mediated reaction must be carefully considered, especially when 307 
MCT1 transporter flux is to be used for simulating PPRgly.  308 
 309 
Fig 3. Sensitivity analysis. 78 model parameters were varied between -99% to +400% of their 310 
default values to identify the maximum mean change in any variable and provide a measure of 311 
sensitivity, , relative to parameter change variation. The 8 most sensitive parameters are 312 
annotated. 313 
 314 
Fig 4. Sensitive model parameters illustrating changes in intracellular lactate 315 
concentration. % mean changes in intracellular lactate concentration as a function of 316 
sensitive parameter manipulation are shown compared to their initial steady state condition. 317 
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Lactate is more susceptible to changes in the equilibrium constant, Keq, than to the Vmax of 318
MCT1 co-transporter kinetics. 319 
 320 
Fig 4 shows the effects of changes in Vmax MCT1 and Keq MCT1 on intracellular lactate 321 
concentrations. The initial parameter was altered from -99 % to +400 % in 21 iterations, as 322 
shown with the 21 bars for each plot. Evidently, intracellular lactate concentration is more 323 
sensitive to the MCT1 equilibrium constant than the Vmax. However, both parameters satisfy 324 
the sensitive criteria threshold  > 10 (Fig 3).  325 
Model parameterisation: cytoplasmic lactate content. 326 
To accurately choose the values for the identified sensitive parameters, the model was fitted to 327 
in vitro intracellular lactate concentration. Liu et al. measured the intracellular lactate 328 
concentration of HepG2 cells during their study on the effects of miR-122 on pyruvate kinase 329 
[33]. Their data was used for comparison of the model simulations of the cytoplasm 330 
concentration of lactate over an extended time course of 48 h. Parameter adjustments were 331 
performed using unconstrained nonlinear optimization as described in the methods section, 332 
such that MCT1 Vmax and MCT1 Keq values were adjusted from 33 mM min-1 and 1, to 2.0×10-333 
3 mM min-1 and 1.15×102 respectively (equilibrium constants are unitless) in Fig 5. Steady state 334 
cytoplasmic levels of lactate in the model, prior to parameter adjustment, were approximately 335 
three times higher than in vitro amounts. A minor adjustment to the MCT1 Vmax parameter 336 
provided a more comparable in vitro  in silico intracellular steady state concentration of 337 
lactate, while simultaneously leaving other variable and flux steady state concentrations largely 338 
unaltered.  339 
 340 
 341 
Fig 5. Intracellular lactate concentration after 48 h: Model intracellular lactate 342 
concentration was aligned with experimental data from HepG2 cells after 48 h. Model 1 343 
simulation represents the lactate concentration pre-parameter adjustment with all model 344 
parameters obtained from the literature. Model 2 simulation represents post-parameter 345 
adjustment. 346 
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347
Model validation: simulating EFA PPRgly and the NAD+/ATP 348 
relationship. 349 
EFA PPRgly experimental data not used for the original parameterisation was used to validate 350 
the model. The in vitro experiment consists of a 1440-min (24 h) incubation in a high glucose 351 
environment (25 mM), followed by extracellular lactate and glucose removal during a 60-min 352 
incubation in unbuffered media prior to EFA. Glucose is reintroduced at t = 1500 min after the 353 
end of the glucose-free incubation, followed by 80 min of measurements. The model replicated 354 
the EFA analysis data by generating the corresponding PPRgly profile for 7.5, 10 and 12.5 mM 355 
of glucose, using the MCT1 flux term (Fig 6). The model output was normalized to the average 356 
protein content of the respective wells. The simulated PPRgly is in good accordance with 357 
experimental observations, with the model being able to accurately simulate PPRgly using the 358 
MCT1 flux only, suggesting that lactate/H+ is likely responsible for glycolytic extracellular 359 
acidification, which is in good agreement with the literature [34 36]. Furthermore, these 360 
simulations implement the cell incubation and media change features that occur prior to EFA, 361 
demonstrating the  to simulate extracellular changes that cannot be measured 362 
experimentally, and predict how the system responds to such perturbations. Simulation of the 363 
in vitro data inclusive of the incubation prior to EFA analysis provides confidence in the 364 
robustness of the model and its output with respect to glycolytic rate.  365 
 366 
Fig 6. Model validation. Model simulation of PPRgly (solid line) compared to in vitro PPRgly 367 
data normalized to protein content. PPRgly data was taken from EFA results (Fig 2) followed 368 
by adjusting each ECAR measurement for respiratory contributions. Prior to t = 1440 min, the 369 
model is simulated to steady state with extracellular glucose concentration of 25 mM (not 370 
shown). At t = 1440 min, extracellular glucose and lactate is removed to replicate in vitro 371 
procedure. At t = 1500 min, glucose is reintroduced at 5 mM allowing comparison to 372 
experimental data.  373 
 374 
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Fig 7 shows further model validation by comparing in silico NAD+/ATP ratio outputs with 375
experimental data [37]. NAD+ concentration in the cytoplasm depends on ATP concentration 376 
in liver cells such that linear increases in ATP lead to linear increases in NAD+ [37]. Model 377 
simulations mirror the experimentally observed positive correlation between ATP and NAD+. 378 
Note, the experimental data used in this section of model validation represents estimated NAD+ 379 
using the L/P derivation method, which may explain the slight discrepancy between the model 380 
output and the data. Overall, the  ability to simulate glycolytic rate, while capturing the 381 
essential dynamics between ATP and NAD+ concentration, demonstrates model fidelity with 382 
respect to the simulation of these two experimental outputs.  383 
 384 
Fig 7. Model validation. Model output was validated by simulating changes in NAD+ as a 385 
function of ATP perturbations. The model was run to steady state before perturbing ATP 386 
concentrations. Experimental data was taken from Devin et. al [37].   387 
 388 
Model predictions  389 
 NAD+/NADH redox state is sensitive to extracellular lactate and glucose 390 
concentration. 391 
The model predictions for the sensitivity of the NAD+/NADH ratio during changes in 392 
extracellular substrates (glucose and lactate) are shown in Fig 8. Fig 8A shows the dynamic 393 
NAD+/NADH time-course profiles for an experimentally relevant range of extracellular 394 
glucose concentrations over a 120-min simulation. The model was first run to steady state (not 395 
shown), followed by perturbations from 0 to 25 mM of extracellular glucose. Each line 396 
represents the percentage change in the NAD+/NADH ratio compared to no change in 397 
extracellular glucose (black dashed line), where the initial conditions for the unperturbed 398 
simulations were 4.9 mM for extracellular glucose and 0.0012 mM for extracellular lactate. 399 
When extracellular glucose concentration is less than 5 mM, the model predicts a continuous 400 
increase in the NAD+/NADH ratio up to a maximum change of 4.8% at 120 min. Conversely, 401 
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for concentrations of glucose greater than 5 mM, the model predicts a decrease in the 402
NAD+/NADH ratio with a maximum decrease of 10.4% at 25 mM after 120 min. These model 403 
outputs suggest that, during hypoglycaemic conditions (< 5 mM), the model favours hepatic 404 
glucose production as opposed to utilisation, which would lead to a reduction in the 405 
concentration in NADH. During elevated glucose exposure (> 5 mM), the model output 406 
predicts increased glycolytic glucose utilisation, which is well documented experimentally (for 407 
every molecule of glucose metabolised via glycolysis, there is a net gain in 2 × NADH 408 
molecules) [38]. Therefore, as extracellular glucose concentrations increase, the glycolytic rate 409 
and NADH concentration increases, leading to a reduction in the NAD+/NADH ratio. The 410 
opposite is predicted when glucose is less than 5 mM.  411 
 412 
Fig 8. Extracellular substrate perturbations. Simulations of the resulting changes in 413 
NAD+/NADH ratio as a function of perturbations in extracellular glucose (A, 0 to 25mM) and 414 
lactate (B, 0 to 40 mM). Each simulation represents the percentage change in NAD+/NADH 415 
compared to an unperturbed simulation (black dashed line) over a 120-min period, with the 416 
perturbation of extracellular substrate occurring at 0 min. Time therefore represents time post-417 
perturbation.  418 
 419 
Fig 8B illustrates the dynamic time-course outputs in NAD+/NADH during perturbations in 420 
extracellular lactate concentration from 0 to 40 mM over a 120-min simulation, representing 421 
the typical concentration range within a tumour microenvironment [39]. Following the initial 422 
steady state, each line represents the post-perturbation percentage change in the NAD+/NADH 423 
ratio compared to no change in extracellular lactate (black dashed line). As the concentration 424 
of extracellular lactate increases, the model predicts a continuous percentage decrease in the 425 
NAD+/NADH with a maximum decrease of 44.2% at 120 min. From a chemical equilibrium 426 
perspective, increases in extracellular lactate will promote uptake of lactate via the MCT1 427 
which will in turn, alter Q to favour the conversion of lactate to pyruvate (when Q > Keq) [40]. 428 
An increase in the conversion of lactate to pyruvate means an increase in NADH and therefore 429 
a decrease in the NAD+/NADH ratio. Ultimately, simulations suggest that an increase in both 430 
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extracellular substrates will favour the reduction of the NAD+/NADH ratio by increasing the 431
concentration of NADH though induction of glycolysis during elevated extracellular glucose, 432 
and by alteration of the pyruvate to lactate conversion through Q during elevated extracellular 433 
lactate exposure.   434 
 435 
Extracellular glucose and lactate influences NAD+/NADH through GAPDH 436 
and LDH fluxes.  437 
Glycolytic regulation of cytosolic NAD+/NADH is maintained through two key enzymes: 438 
GAPDH and LDH. Perturbations in the reaction fluxes of these enzymes directly affects the 439 
NAD+/NADH ratio within the model. Therefore, the sensitivity of these key enzymes towards 440 
changes in the extracellular substrate environment was investigated. Fig 9 shows the resulting 441 
simulated changes in reaction fluxes for GAPDH and LDH during perturbations in extracellular 442 
glucose (0 to 25 mM, top panel) and extracellular lactate (0 to 40 mM, bottom panel) during a 443 
120-minute simulation. Each line represents the percentage change in the enzyme flux 444 
compared to no change in extracellular glucose (black dashed line), using the same initial 445 
conditions as in Fig 8.  446 
 447 
Fig 9. Extracellular substrate perturbations. Simulations of the resulting changes in 448 
GAPDH and LDH flux as a function of perturbations in extracellular glucose (0 to 25mM, top 449 
row panels) and lactate (0 to 40 mM, bottom row panels). Each simulation represents the 450 
percentage change in GAPDH and LDH flux compared to an unperturbed simulation (black 451 
dashed line) over a 120-min period, with the perturbation of extracellular substrate occurring 452 
at 0 min. Time therefore represents time post-perturbation.  453 
 454 
Simulations predict that for elevated extracellular glucose (> 5 mM), GAPDH and LDH 455 
enzyme fluxes increase up to a maximum of 84% and 37% respectively. During diminished 456 
extracellular glucose concentrations (< 5mM), the model predicts negative GAPDH and LDH 457 
fluxes, with a maximum decrease of -40% and -8.8% respectively.  Negative reaction fluxes 458 
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illustrate a switch in metabolic directionality whereby the reverse reaction governed by each 459
enzyme is favoured. Consequently, when extracellular glucose concentration is high (> 5 mM), 460 
the model predicts increased formation of NADH through accelerated GAPDH flux, and 461 
increased NAD+ formation through accelerated LDH flux. While both NADH and NAD+ 462 
production is elevated, GAPDH is predicted to be more sensitive to extracellular glucose than 463 
LDH, with simulations suggesting that GAPDH flux is more than twice as fast as LDH. This 464 
results in a net increase in NADH, corresponding to the decreased NAD+/NADH ratio seen in 465 
Fig 8.  466 
The bottom panel in Fig 9 shows how changes in extracellular lactate concentration affects 467 
GAPDH and LDH reaction flux. For all increased concentrations of extracellular lactate, 468 
simulations predict negative reaction fluxes for GAPDH, with a maximum change of 318% 469 
after 120 minutes. For the same changes in extracellular lactate concentration, the model also 470 
predicts a negative reaction flux for LDH, with a maximum of 716% over 120 minutes. 471 
Negative enzyme flux profiles suggest favouring of the production of NAD for GAPDH 472 
accompanied by the favouring of production of NADH for LDH. Overall, during increases in 473 
extracellular lactate concentration, the model predicts that there will again be a net increase in 474 
NADH concentration, given the differences in sensitivity between GAPDH and LDH.  475 
It is unsurprising that increased extracellular lactate stimulates an increase in the reverse LDH 476 
flux, as tumour cells growing under aerobic conditions can utilise lactate as an energy source 477 
by uptake followed by conversion back to pyruvate, also known as metabolic symbiosis [39]. 478 
Lactate as an energy source in this instance spares glucose, making it more readily available 479 
for hypoxic tumour cells, with oxidative tumour cells preferring lactate as a source of metabolic 480 
fuel [41]. Furthermore, model predictions are in good accordance with the literature, which 481 
suggests that oxidation of lactate to pyruvate under these circumstances sustains NADH 482 
production in order to mitigate tumour oxidative stress [42]. While glycolytic regulation in 483 
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general is complex, GAPDH is recognised as an important regulatory enzyme in living cancer 484
cells, suggesting that GAPDH exhibits the most positive control on glycolytic flux according 485 
to metabolic control analysis [43]. GAPDH within the glycolytic pathway is regulated by ATP 486 
and NAD+, and with respect to aerobic glycolysis, GAPDH is highly expressed, emphasising 487 
its role in supporting the elevated demand for glycolysis [44]. Model simulations predict that 488 
the NAD+/NADH ratio may be manipulated through changes in GAPDH and LDH flux, as a 489 
function of perturbations in extracellular glucose and lactate.  490 
 491 
Model considerations and applications. 492 
The model presented here extends the mathematical/computational representation of in vitro 493 
EFA with regards to glycolytic rate. Other models such as the MITOsym , provide an 494 
outstanding computational representation of EFA, boasting inclusion of both oxidative and 495 
respiratory-based bioenergetic processes [45]. However, the MITOsym  model is a 496 
significantly reduced representation of the bioenergetic portrait, aimed at capturing the key 497 
aspects of mitochondrial function in a whole cell environment [45]. In doing so, NADH is not 498 
explicitly modelled, but instead inferred from utilisation of pyruvate. Moreover, glycolysis 499 
itself is captured through a reduced set of ODEs, with ECAR computed using pyruvate-to-500 
lactate flux (representative of LDH) [45]. Here, glycolytic rate is modelled using the glycolytic 501 
pathway in its entirety, including dynamic proton and metal ion buffering, thermodynamics 502 
and reaction equilibria. In doing so, the model is able to represent glycolytic rate specifically 503 
in the form that EFA measures it, i.e. PPRgly, using the MCT1 proton-lactate efflux process 504 
(Fig 6). Moreover, NAD+/NADH in this model is explicitly represented, capturing the 505 
relationship between NAD+ and ATP (Fig 7). Therefore, the model presented here is better 506 
suited for simulating and investigating glycolytic rate in the form of PPRgly. However, a caveat 507 
of this model is that it does not include TCA or oxidative metabolism and therefore its output 508 
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is limited to represent non-oxidative energy metabolism only. Furthermore, while Ca2+ is 509
present as a variable in the model, the omission of mitochondrial metabolism limits the models 510 
ability to explicitly capture other important regulators of the cytosolic NAD+/NADH ratio, for 511 
example, how the translation of cytosolic Ca2+ transients by the mitochondria results in 512 
transmission of NADH from the mitochondria itself to the cytosol [46]. The model predicts 513 
that the availability of extracellular substrates influences the NAD+/NADH ratio, particularly 514 
extracellular lactate (Fig 8). This is informative as in vitro derivation of the NAD+/NADH ratio 515 
by forcing chemical equilibrium using elevated concentrations of extracellular lactate could 516 
therefore lead to spurious estimations. Moreover, simulations predict that changes in GAPDH 517 
and LDH flux, as a function of perturbations in extracellular substrate, significantly influence 518 
glycolytic rate and the NAD+/NADH ratio (Fig 9). Indeed, the relationship between these 519 
enzymes and glycolytic rate is strengthened in Fig 3, where the parameters Keq GAPDH and 520 
Vmax LDH score as mildly sensitive with respect to PPRgly. The relationship between 521 
extracellular substrate and NAD+/NADH could be exploited, using the model to assist the 522 
design of experiments whereby extracellular substrates are deliberately manipulated to yield 523 
variance in the NAD+/NADH ratio. Such methods could perhaps be used to mimic inter-524 
individual variation, metabolic disorders or cellular metabolic variations. At the very least, 525 
these simulations, which are in accordance with literature and in vitro outputs [10,41 43], 526 
suggest that the composition of extracellular substrates during cancer cell culture should be 527 
considered carefully due to their potential influence on the cellular free NAD+/NADH ratio and 528 
bioenergetic function.  529 
Conclusions 530 
In this study, the sensitivity of the cytosolic free NAD+/NADH ratio towards perturbations in 531 
extracellular glucose and lactate was assessed using an in silico model of hepatocarcinoma 532 
glycolytic flux. The model predicts that the NAD+/NADH ratio is particularly sensitive to 533 
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changes in extracellular lactate whereby elevated concentrations, comparable to those found in 534
a tumour microenvironment, can result in a decrease in the NAD+/NADH ratio of up to 44.2% 535 
after 2 hours. The model was used to investigate how changes in extracellular glucose and 536 
lactate influence cancer bioenergetics through GAPDH and LDH flux, predicting that GAPDH 537 
and LDH are most sensitive to glucose and lactate respectively. Maximal changes in the 538 
enzyme fluxes of 318% and 716% for GAPDH and LDH are achieved, when extracellular 539 
glucose and lactate concentrations are 25 mM and 40 mM respectively. Overall, the model can 540 
be used to simulate experimentally challenging situations, such as circumventing the need to 541 
artificially alter the state of lactate equilibrium during estimation of the cytosolic free 542 
NAD+/NADH, while providing a platform from which experimental design of extracellular 543 
substrate manipulation can be assisted.  544 
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